Skip to content

Bromocriptin and rheumatoid arthritis

Evaluation of Bromocriptin effect on disease activity index in rheumatoid arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201008121778N3
Enrollment
80
Registered
2010-08-12
Start date
2010-04-30
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Seropositive rheumatoid arthritis

Interventions

Intervention 1: two placebo tablet per day for 3 months. Intervention 2: Bromocriptin oral pills 2.5 mg two tablet per day for 3 months.
Placebo
Treatment - Drugs
two placebo tablet per day for 3 months
Bromocriptin oral pills 2.5 mg two tablet per day for 3 months

Sponsors

Vice chancellor of research, Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Rheumatoid arthritis patients (proved by ACR criteria) that greater than 16 years old with active R.A (DAS>4) despite conventional thrapy. Exclusion criteria: Drug reaction, lapse from the study, Immigration or death, containdications for bromocriptin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical and laboratory findings. Timepoint: Before the study and 3 months later. Method of measurement: DAS28, ESR, VAS, Prolactin.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansour Salesi

Isfahan University of Medical Sciences

salesi@med.mui.ac.ir+98 31 1265 1983

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026